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Abstract
With the epidemiological transition, causes of death shifted 
from communicable to non-communicable diseases (NCDs) 
and life expectancy increased, as these NCD deaths oc-
curred later in life. However, in the United States, over the 
past years, life expectancy has been stagnating or decreas-
ing despite decreasing NCD mortality rates. Analyses of the 
most important underlying causes of death with increasing 
premature mortality reveal that psychoactive substance 
use played a crucial role for these increases. Furthermore, it 
can be shown, that a high proportion of the increased pre-
mature mortality and decreased life expectancies hap-
pened in lower socio-economic strata. Substance use poli-
cies should thus focus on lowering the gap between sub-
stance-attributable mortality in higher versus lower 
socioeconomic strata. © 2018 S. Karger AG, Basel
The Role of Non-Communicable Disease in 
Premature Mortality 
As a consequence of the so-called epidemiologic tran-
sition in most parts of the world [1, 2], non-communica-
ble diseases (NCDs) constitute an overwhelming major-
ity of global premature mortality [3, 4]; in fact, the NCDs 
included as indicators in the World Health Organization 
Global Action Plan for the Prevention and Control of 
NCDs 2013–2020 [5] (i.e., cardiovascular disease, cancer, 
respiratory disease, and diabetes), comprised 70% of all 
deaths globally, and 80% of all premature NCD deaths in 
2010 [6]. The reduction of premature mortality from 
NCDs is also target 3.4 of the United Nations’ Sustainable 
Development Goals [7].
Part of the epidemiological transition, along with the 
shift from infectious diseases to NCDs, has been the in-
crease of life expectancy [1, 8]; and in fact, life expectancy 
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has been increasing in most countries over the past de-
cades [9, 10]. Given this situation, it is hard to imagine 
that life expectancy in a major country will be decreasing 
despite progress in NCD mortality. Yet, we seem to face 
this situation for the United States in current years. In the 
following sections, we discuss the current trends in life 
expectancy in the United States, and analyze causal influ-
encing factors on these trends.
Trends in Life Expectancy and Premature Mortality 
in the United States
The most recent data on life expectancy for the United 
States showed a stagnation over the past 5 years [11–13], 
with some populations like middle-aged white non-His-
panics or people living in rural areas experiencing in-
creasing mortality rates and decreasing life expectancy 
[14, 15]. 
This stagnation in life-expectancy was evident de-
spite sizable declines in mortality between 2010 and 
2015 in the major NCDs (Table 1). In fact, 4 of the 5 most 
important non-communicable causes of death in the 
United States decreased in age-standardized mortality 
rates (diseases of the heart, malignant neoplasms, chron-
ic lower respiratory diseases, cerebrovascular diseases), 
with only the age-standardized rates of diabetes melli-
tus, the relatively least important cause of death, increas-
ing [12, 16].
Years of potential life lost (YLLs) are more closely re-
lated to life expectancy than mortality rates. Table 2 gives 
an overview of YLLs before the age of 75 by cause of death 
between 2010 and 2015, based on the recent overview 
publication of the National Center for Health Statistics 
[13]. In this measure, the overall YLLs for NCDs went 
down, mainly driven by decreases in cancer mortality 
and – to a lesser degree – heart disease mortality. YLLs 
due to the smaller categories of chronic lower respiratory 
diseases and diabetes increased. 
What Causes of Death Were Associated with 
Increases in Premature Mortality?
In this section, we discuss the causes of death mainly 
related to increases in YLLs. We will concentrate on the 
links to psychoactive substance use as risk factors (over-
views on psychoactive substances as risk factors: for alco-
hol see [17]; for illicit drugs see [18]; for tobacco see [19]). 
Alcohol and tobacco use are major risk factors for the 4 
most important NCDs in the World Health Organization 
Global Action Plan for the Prevention and Control of 
NCDs [5], but, as will be shown below, both of these sub-
stances and other psychoactive substances are also caus-
ally related to other NCD causes of death such as liver 
cirrhosis or mental disorders [20], as well as in commu-
nicable disease and injury mortality [17–19].
The largest contributor to YLL increases in the United 
States was unintentional injuries (Table 2). A causal link 
between alcohol use and all kinds of unintentional inju-
ries has been established for a long time [21, 22], with 
relatively high attributable fractions [23, 24]. In addition, 
pharmaceutical and illicit drug use has been linked to 
many types of unintentional injuries [18], in particular, 
traffic injuries [25]. For the United States specifically, poi-
sonings were important, and various kinds of psychoac-
tive substances played a key role there (especially phar-
maceutical and illicit drugs: [26]; but also alcohol: [27]). 
As can be seen in Table 2, YLLs from poisonings had a 
huge increase in the past 5 years.
Table 1. Percentage changes in top NCD causes of death in the United States between 2010 and 2015
Cause of death International classification
of diseases and related
health problems code
Age-standardized 
death rate per 
100,000 in 2010*
Age-standardized 
death rate per 
100,000 in 2015*
Percentage 
change, %
Rank in
2015
Diseases of heart (I00–I09, I11, I13, I20–I51) 179.1 168.5 –5.9 1
Malignant neoplasms (C00–C97) 172.8 158.5 –8.3 2
Chronic lower respiratory diseases (J40–J47) 42.2 41.6 –1.4 3
Cerebrovascular diseases (I60–I69) 39.1 37.6 –3.8 5
Diabetes mellitus (E10–E14) 20.8 21.3 2.4 7
Total NCD (based on above) 454.0 427.5 –5.8
* Based on US standard population of 2000: [79].
Sources: for 2010: [16]; for 2015: [12].
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Intentional injuries also had marked increases in YLLs 
over the last 5 years. Suicide mortality has been shown to 
be causally impacted by alcohol and other psychoactive 
substance use. Bagge and Sher [28] developed a theoreti-
cal framework with complex causal chains for distal and 
proximal relations. In terms of the epidemiological defi-
nition of causality [29, 30], 2 main pathways from sub-
stance use to suicide can be distinguished (e.g., [31] spe-
cifically for alcohol, but the arguments apply to other sub-
stances as well): there is an acute impact of using 
substances via disinhibition, impulsiveness, and impaired 
judgment, and substances may also be used as a means to 
ease the distress associated with committing an act of sui-
cide (e.g., [32]). Furthermore, there is a long-term effect 
of substance-use disorders on suicide mortality risk, as 
they can cause high distress often associated with a break-
down of social relations and social marginalization, and 
without any hope of improvement [33, 34]. The relative 
risks for suicide mortality of heavy use of psychoactive 
substances are high, and the burden of suicide attribut-
able to various substances is only surpassed by the sub-
stance-attributable burden due to depression [35].
As for the connection of substance use to intentional 
injuries from violence and aggression, the evidence can 
Table 2. YLL before age 75 for selected major causes of death United States 2010 and 2015 and proportional change
Cause of death Age-standardized 
YLLs* 2010
Age-standardized 
YLLs* 2015
Proportional 
change, %
ICD code
All causes 6,643 6,758 1.7
Causes of death with decreased YLLs
Malignant neoplasms 1,396 1,283 –8.1 C00–C97
Trachea, bronchus, and lung 331 273 –17.5 C33–C34
Colorectal 125 123 –1.4 C18–C21
Prostate 52 47 –10.5 C61
Breast 262 242 –7.8 C50
Diseases of heart 972 957 –1.6 I00–I09, I11,
I13, I20–I51
Ischemic heart disease 577 530 –8.1 I20–I25
Cerebrovascular diseases 169 161 –4.9 I60–I69
Nephritis, nephrotic syndrome, and nephrosis 73 69 –5.2 N00–N07, N17–N19,
N25–N27
HIV disease 77 50 –34.2 B20–B24
Causes of death with increased YLLs
Unintentional injuries 1,025 1,172 14.3 V01–X59, Y85–Y86
Motor vehicle-related injuries 401 405 1.1 V02–V04, V09.0, V09.2, 
V12–V14, V19.0–V19.2, 
V19.4–V19.6, V20–V79, 
V80.3–V80.5,
V81.0–V81.1,
V82.0–V82.1,V83–V86, 
V87.0–V87.8,
V88.0–V88.8, V89.0, V89.2
Poisoning 380 531 39.9 A40–A49
Suicide 385 429 11.3 U03, X60–X84, Y87.0
Homicide 239 252 5.4 U01–U02, X85–Y09, Y87.1
Chronic liver disease and cirrhosis 164 190 16.1 K70, K73–K74
Chronic lower respiratory diseases 172 176 2.0 J40–J47
Diabetes mellitus 158 176 11.4 E10–E14
Influenza and pneumonia 71 74 3.9 J09–J18
Alzheimer’s disease 12 13 11.1 G30
* YLL, years of potential life lost; age-standardization based on US standard population of 2000: [78].
Source: [13].
HIV, human immunodeficiency virus.
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be separated between alcohol use and other substances. 
For the causal impact of alcohol on violence and aggres-
sion, there is good evidence, including experimental evi-
dence [36–38]. For illicit drugs, based on the classic paper 
of Goldstein [38], 3 different types of violence should be 
distinguished: systemic violence refers to interpersonal 
aggression among persons involved in the drug trade as a 
consequence of the illicit market; economic compulsive 
violence refers to violence in the course of criminal activ-
ity to obtain resources to support drug use; and psycho-
pharmacological violence refers to causation of violent 
behavior by the psychobiological effects of the drug. The 
latter was most often linked with amphetamines, cocaine, 
barbiturates, and phencyclidine use, while there is little 
evidence to link heroin, marijuana, or other hallucino-
gens. 
A 2016 systematic review [39] found some evidence 
for a connection to systemic violence but little evidence 
supporting the connection to economic compulsive vio-
lence. In addition, reviews have concluded that the evi-
dence for a psychopharmacological causation is weak 
[40].
The next largest category with respect to increases in 
YYLs is chronic liver disease and cirrhosis (Table 2), 
both of which are linked to alcohol use [41], and to drug 
use via hepatitis infections [42]. Currently, the majority 
of liver cirrhosis in the United States is estimated to be 
attributable to alcohol [43]. Chronic lower respiratory 
diseases follow, which had already been mentioned in 
the First Surgeon General’s Report as being impacted by 
tobacco use [44]. Next is diabetes, which has been re-
lated to alcohol use [45, 46], albeit in a curvilinear, j-
shaped way for at least some population groups. While 
lower consumption levels may have protective effects, 
heavy drinking and alcohol use disorders have detri-
mental effects ([45–47]; see [48] specifically for the 
Americas).
Influenza and pneumonia are impacted by alcohol and 
tobacco use [49, 50]. Finally, Alzheimer’s disease and all 
forms of dementia are impacted by alcohol use, especial-
ly heavy alcohol use [51]. The YLLs for Alzheimer’s dis-
ease and all forms of dementia are relatively small in ab-
solute terms, as these diseases often occur late in life. 
However, a recent analysis of French hospitalization data 
in more than 30 million patients revealed, that while the 
overall alcohol-attributable fraction for dementia was 
low, more than 50% of all early onset dementias (defined 
as onset before age 65 years) were either alcohol-related 
dementias [52, 53], or in people with alcohol use disor-
ders [54]. In other words, in the age groups impacting life 
expectancy, alcohol was a major risk factor for all types of 
dementia. 
The importance of substance use was also underlined 
by causes of death being 100% attributable to alcohol or 
drug use (not displayed in Table 2), which increased 
markedly over the past years (between 2010 and 2014 by 
19 and 16% for drug-attributable and alcohol-attribut-
able causes of death respectively [55]).
In sum, almost all the major causes of death contribut-
ing to YLLs (exception: diabetes) were causally and 
strongly detrimentally linked to the use of psychoactive 
substances, and thus, such substance use seems to play a 
major role in the declining life expectancies in the United 
States (see [56], for other examples of reversals of trends 
in life expectancy due to substance use). This does not 
mean that other risk factors are not involved in impacting 
the current mortality patterns, both in interaction with 
substance use [57] and as independent risk factor [58]. To 
give but an example: high body mass index is a risk factor 
with one of the fastest rising attributable disease burden 
over the past decades globally [58] and for the United 
States (own calculations based on [59]) and is also related 
to a number of disease outcomes discussed above. Exam-
ples for the impact of body mass index would be chronic 
liver disease and cirrhosis [60] or diabetes [58], the for-
mer probably in interaction with alcohol use [61].
The Role of Socioeconomic Status
Socioeconomic status plays an increasing and crucial 
role in the recent developments of life expectancy [62]. 
Between 2001 and 2014, the life expectancy at age 40 of 
the highest income quartile increased by around 0.2 
years per year, whereas the increases for the lowest 
 income quartile were only by 0.1 years or less. Through-
out this period, the 1% with the highest income could 
on  average expect to live about 15 (men) and 10 
years  (women) longer at age 40 than a person of the 
 bottom 1%. 
A widening of the socioeconomic gap in mortality in 
the United States has been observed in several studies 
over the past decades, particularly in middle-aged people 
[14, 63]. While all-cause mortality was decreasing in mid-
dle-aged people with more than secondary education, the 
opposite was true for people with a high school degree or 
less schooling [14]. The increase in mortality was found 
to be particularly high in unintentional injuries including 
poisonings, closely followed by intentional self-harm and 
chronic liver cirrhosis [14]. Research on injury mortality 
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among youth in the United States showed high disparities 
in homicide and unintentional injury mortality with at 
least twofold mortality rates among more deprived youth 
[64]. Similar results were found among the general popu-
lation with increased risks of unintentional injuries, sui-
cide, and homicide for people from more deprived areas 
[63]. Furthermore, socioeconomic inequalities in motor 
vehicle fatalities in the United States increased strongly 
from 1995 to 2010 [65]. While the fatality rates per miles 
travelled dropped in socioeconomic groups with higher 
education, fatalities among persons with less than high 
school education increased. 
Chronic liver disease and cirrhosis as well as diabetes 
mortality were also associated with trends for a widening 
the gap between the lower and higher socioeconomic sta-
tus [63, 66]. Rate ratios for both conditions increased 
from around 1.5 in the early 1990s to 2.0 (2005–2009) 
[63]. Overall, these findings indicate that stagnation and 
decline in life expectancy are, to a large extent, at the ex-
pense of people of lower socioeconomic status. 
Substance use is likely to play a key role in these devel-
opments. Smoking-attributable mortality [67], overdose 
deaths from prescription drugs [68, 69], as well as alco-
hol-attributable mortality [70] have been clearly linked to 
the socioeconomic status. 
To give further examples, the prevalence of current 
smoking overall decreased between 2005 and 2015 by 
28%. However, declines were much stronger among 
people with high socioeconomic status, exacerbating so-
cioeconomic differences that already existed [71]. The 
findings regarding the prevalence of alcohol use and 
heavy episodic drinking in different socioeconomic 
groups in the United States are mixed [72, 73]. Some 
research found people of lower socioeconomic status to 
be more likely to drink 5 dirks or more on a drinking 
occasion compared to people of high socioeconomic 
status [74]. However, alcohol use has been discussed as 
a factor that contributes to socioeconomic differences in 
mortality above and beyond differences in patterns of 
drinking [57].
A recent study from the United States supports the rel-
evance of alcohol and other substance use for the socio-
economic mortality gap, showing that about 70% of the 
socioeconomic differences in mortality could be ex-
plained by tobacco and alcohol use, and by physical inac-
tivity [74]. Overall, the evidence suggests that increases in 
socioeconomic differences in mortality are contributing 
to the stagnating life expectancy and that these changes 
are strongly influenced by substance use and related 
causes of death. 
Conclusions for Substance Use Policies
Substance use has been shown to be implicated in the 
current stagnation of life expectancy in the United 
States, and this impact was clearly more pronounced for 
lower socioeconomic strata than for higher socioeco-
nomic strata. What are the consequences for substance 
use policies? Currently, most such policies are examined 
for the effectiveness or cost-effectiveness in reducing 
substance-related harm (see for example, the so-called 
best buys for reducing substance-attributable disease 
burden – [75, 76]). However, in future, in addition to ef-
fectiveness and cost-effectiveness, we need to examine 
the impact of any policy on the premature mortality gap 
between lower and higher socioeconomic strata. In fact, 
given the results of our analyses and general consider-
ations on governance for psychoactive substances [77], 
the ability to reduce the premature mortality may be the 
most important criterion to choose between overall 
cost-effective interventions. Otherwise, we may be left 
with a situation, where the overall disease harm by such 
substances increases strongly despite stagnating or only 
moderately increasing prevalence of use (e.g., for alco-
hol [78]).
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